AzTrials
AzTrials

AmblyopiaNCT03505606

New Visual Acuity and Crowding Tests for Better Detection of Amblyopia

A study testing Visual acuity tests in people with Amblyopia, run by Anglia Ruskin University at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Amblyopia, or 'lazy eye', is the reduction in vision usually in one eye, due to abnormal visual development without organic cause. It is a preventable and leading cause of monocular vision loss (prevalence of around 3%) and increases lifetime risk of bilateral visual impairment from 10% in the general population, to… Read more about this study

Who is it for?
Ages 3 to 11 yearsHealthy volunteers can take part
Conditions the study is for
Amblyopia
What is being tested?
Visual acuity tests
Could I receive a placebo?
No, everyone receives an active treatment
How many people
76 participants
Where
1 siteUnited Kingdom
Study dates
1 Jan 2019to 1 Jul 2021
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 11 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Test participants; Male and female 3 to 11-year-old children diagnosed by ACPOS clinicians as likely having amblyopia (strabismic or anisometropic). They will be tested following 6 weeks (or more) of refractive adaption.
  • Control Participants; Male and female 3 to 11-year-old children who have been falsely referred into the Hospital Eye Service (ACPOS) by the visual screening service, but have satisfactory visual functions, as per the national screening guidelines.
  • All participants must be able to complete the Sonsken logMAR Test (SLT) either verbally or via use of a matching card.

Who cannot join

  • Uncorrected refractive error.
  • The presence of any other vision limiting medical condition, not listed in the inclusion criteria.
  • Any prior or existing medical history of epilepsy or seizures.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Anglia Ruskin University Eye Clinic

    Cambridge, Cambridgeshire, CB11PT

Other trials in United Kingdom

About this study

Official title: Examination of New Visual Acuity and Clinical Crowding Tests for Better Detection of Amblyopia

Amblyopia, or 'lazy eye', is the reduction in vision usually in one eye, due to abnormal visual development without organic cause. It is a preventable and leading cause of monocular vision loss (prevalence of around 3%) and increases lifetime risk of bilateral visual impairment from 10% in the general population, to 18% in amblyopes.

In the UK, vision screening in children aims to detect amblyopia and other undiagnosed visual conditions. Laboratory research suggest that amblyopia could be better detected by modifying standard clinical vision tests to enhance and quantify "crowding". Crowding is the negative effect that surrounding features have on the visibility of a target. Crowding distance and crowding magnitude are considerably greater in amblyopic eyes than in normal healthy eyes. Modifications that should lead to improved amblyopia detection are 1) place letters closer together on a vision chart, 2) define letters by contrast, rather than luminance, and 3) use a new thinner font in the form of numbers, to allow crowding distance in central vision to be measured. In this project, these modifications will be tested in amblyopic children for the first time.

Amblyopic children aged 3 to 11 years (n=32) will be recruited from ACPOS (Addenbrooke's Community Paediatric Ophthalmology Service) at ARU. They will have their vision measured with the three modified tests as well as an uncrowded test. The child will view letters and numbers on a computer screen and respond (verbally or by indicating their choice on a matching card). Testing is fun and game-like with breaks for rewards. Results will be compared to standard vision measurement (SLT: Sonksen LogMAR Test) from the child's ACPOS visit. Amblyopic data will be compared to control data from normal healthy children aged 3 to 11 years (n=200), and age-matched children with normal vision (n=16) from ACPOS (false referrals from school screening).

Read the detailed description

In the UK, a national vision screening is employed to detect amblyopia and other undiagnosed visual conditions in school-aged children, so that they can be managed effectively. Better detection of amblyopia could be achieved by modifying current visual acuity tests, which measure the spatial resolution limit (or capacity for clarity and sharpness) of vision and by measuring crowding distance; previously unmeasured in a clinical setting. By strengthening crowding magnitude, and better quantifying its spatial distance in paediatric populations, it is hoped that the ability to detect amblyopia, and monitor its improvement with treatment will be significantly enhanced.

Three recent suggestions regarding modifications to current visual acuity tests may lead to improved detection of crowding-sensitive conditions, such as amblyopia. First, closer placement of surrounding letters to the target letter should increase the magnitude of crowding in the amblyopic eye in particular, leading to increased visual acuity differences between eyes. Second, contrast modulated stimuli should enhance crowding in amblyopic eyes. Third, a new thinner font will allow clinical measures of foveal crowding distance. In this project, these three modifications will be tested for the first time in the target clinical population.

Several studies reported that optotypes (letters or symbols) on a vision chart should be placed closer together than they currently are on commercially-available charts, which use 2.5 to 5 stroke-widths separation between target and neighbouring letters. Closer placement disrupts target optotype identification in normal peripheral vision and in central vision of amblyopic eyes due to crowding. In one vision test in the proposed study, a laterally-reversible target letter (e.g., H, O, T or V) will be surrounded by four other letters (U, A, L, C). This arrangement, in which letters were separated by 0.5 optotype widths (or 2.5 stroke widths) was first formally used in the Cambridge Crowding Test. In the proposed experiments, the surrounding letters will be placed 1 stroke-width away from the target letter, the optimal position recommended by recent studies.

Visual acuities for target letters will be measured for both amblyopic and non-amblyopic eyes of child participants, in a clinical environment. These results will be compared with visual acuities acquired during the clinical appointment using the Sonksen logMAR Test (SLT), which is the standard visual acuity test used in Cambridge University Hospital, Addenbrooke's Orthoptic Department

In the Sonksen logMAR Test (SLT), a single line of 4 letters separated from each other by 5 stroke-widths (or 1 optotype width), is contained within a box, separated from the letters also by 5 stroke-widths.

Recognition of target optotypes created by contrast-differences (second-order stimuli) is prone to greater crowding effects than is recognition of optotypes created by luminance-differences (first-order stimuli). This effect is present in normal vision, however even greater visual losses for contrast-defined targets, as well as stronger crowding effects, have been reported in amblyopia. By presenting a contrast-modulated (CM) target letter (H, O, T or V) surrounded by four other letters (U, A, L, C) placed 1 stroke-width away (in the modified Cambridge Crowding Test arrangement), this research aims to examine whether this second-order vision test will exaggerate differences between the eyes of amblyopic children, when compared to those measured in visually 'normal' children. The results will again be compared to those obtained with the Sonksen logMAR test (SLT), a first-order vision test, to compare their sensitivities to amblyopia detection.

Finally, crowding distance, the spatial distance over which crowding occurs, in normal foveal (central) vision is small (2-4 arcmin) and cannot be measured with current standard clinical optotypes due to their large size (5 arcmin for 0.0 logMAR acuity). To get around this difficulty, a new vision test was recently created to quantify the crowding distance or "critical spacing" of crowding . It uses a new "Pelli" font, which is much thinner horizontally than standard clinical fonts, allowing the optotypes to get closer to each other in physical space. This 'Crowding Distance Test' permits quantification of the critical spacing of crowding for the first time in a clinical population. The new "Pelli" font, each optotype appearing like tall skinny numbers, has already been trialled on 'visually normal' school-aged children, but not yet examined on children with greater sensitivity to visual crowding, i.e., amblyopes. The third vision test in the proposed research, will investigate whether or not "crowding distance" measures made in each eye, results in greater inter-ocular differences, leading to better detection of anisometropic and strabismic amblyopia than does the current clinical standard visual acuity test, the Sonksen logMAR test (SLT).

By using closer first-order target optotypes, second-order target optotypes, and quantifying crowding distance in paediatric populations, the ability to detect amblyopia and monitor amblyopia treatment, could be significantly improved for the first time since the 1960s. At that time crowding was first quantified in a clinical population of adult amblyopes and was subsequently incorporated into commercially available tests as best practice.

Conditions
Amblyopia
Being tested
Visual acuity tests
Keywords
Amblyopia, Visual Acuity, Crowding
Medical subject headings
Amblyopia, Crowding

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Visual acuity testsDiagnostic test

    Also called Contrast-modulated Cambridge Crowding test, Crowding Distance Test, Enhanced Cambridge Crowding test

    Participants to have visual acuity tested with the three modified vision tests.

Study groups in NCT03505606
Study groupRoleWhat they receive
ControlActive comparatorVisual acuity tests on control participants
Receives: Diagnostic Test: Visual acuity tests
Strabismic/mixed amblyopesExperimentalVisual acuity tests on strabismic/mixed amblyopic participants.
Receives: Diagnostic Test: Visual acuity tests
Anisometropic amblyopesExperimentalVisual acuity tests on anisometropic amblyopic participants.
Receives: Diagnostic Test: Visual acuity tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual Acuity (LogMAR)

    Threshold visual acuity measured in LogMAR

    Measured: Visual acuities for each participant were measured at a single time point, on a single day; day one of each participants' recruitment.

  2. Foveal Crowding Distance (Degrees)

    Foveal critical crowding distance measured in degrees

    Measured: Crowding distances for each participant were measured at a single time point, on a single day; day one of each participants' recruitment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Apr 2018
  2. Study start1 Jan 2019
  3. Primary completion31 May 2021
  4. Study completion1 Jul 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
76 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03505606
Sponsor's protocol ID
FST/FREP/17/739
Status last verified
Aug 2024
First submitted
4 Apr 2018
Last updated
21 Oct 2024
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Pseudo-anonymised data to be uploaded to ARRO, the university data storage system.

Publications

  • Chung ST, Li RW, Levi DM. Crowding between first- and second-order letter stimuli in normal foveal and peripheral vision. J Vis. 2007 Mar 9;7(2):10.1-13. doi: 10.1167/7.2.10.

    PubMed 18217825
  • Chung ST, Li RW, Levi DM. Crowding between first- and second-order letters in amblyopia. Vision Res. 2008 Mar;48(6):788-98. doi: 10.1016/j.visres.2007.12.011. Epub 2008 Jan 31.

    PubMed 18241910
  • Danilova MV, Bondarko VM. Foveal contour interactions and crowding effects at the resolution limit of the visual system. J Vis. 2007 Nov 27;7(2):25.1-18. doi: 10.1167/7.2.25.

    PubMed 18217840
  • FLOM MC, WEYMOUTH FW, KAHNEMAN D. VISUAL RESOLUTION AND CONTOUR INTERACTION. J Opt Soc Am. 1963 Sep;53:1026-32. doi: 10.1364/josa.53.001026. No abstract available.

    PubMed 14065335
  • Formankiewicz MA, Waugh SJ. The effects of blur and eccentric viewing on adult acuity for pediatric tests: implications for amblyopia detection. Invest Ophthalmol Vis Sci. 2013 Oct 23;54(10):6934-43. doi: 10.1167/iovs.13-12543.

    PubMed 24071956
  • Hairol MI, Formankiewicz MA, Waugh SJ. Foveal visual acuity is worse and shows stronger contour interaction effects for contrast-modulated than luminance-modulated Cs. Vis Neurosci. 2013 May;30(3):105-20. doi: 10.1017/S0952523813000102. Epub 2013 Apr 25.

    PubMed 23731769
  • Huurneman B, Boonstra FN, Cox RF, Cillessen AH, van Rens G. A systematic review on 'Foveal Crowding' in visually impaired children and perceptual learning as a method to reduce Crowding. BMC Ophthalmol. 2012 Jul 23;12:27. doi: 10.1186/1471-2415-12-27.

    PubMed 22824242
  • Lalor SJH, Formankiewicz MA, Waugh SJ. Crowding and visual acuity measured in adults using paediatric test letters, pictures and symbols. Vision Res. 2016 Apr;121:31-38. doi: 10.1016/j.visres.2016.01.007. Epub 2016 Feb 18.

    PubMed 26878696
  • Siderov J, Waugh SJ, Bedell HE. Foveal contour interaction for low contrast acuity targets. Vision Res. 2013 Jan 25;77:10-3. doi: 10.1016/j.visres.2012.11.008. Epub 2012 Nov 29.

    PubMed 23200866
  • Song S, Levi DM, Pelli DG. A double dissociation of the acuity and crowding limits to letter identification, and the promise of improved visual screening. J Vis. 2014 May 5;14(5):3. doi: 10.1167/14.5.3.

    PubMed 24799622
  • Wong EH, Levi DM, McGraw PV. Is second-order spatial loss in amblyopia explained by the loss of first-order spatial input? Vision Res. 2001 Oct;41(23):2951-60. doi: 10.1016/s0042-6989(01)00189-4.

    PubMed 11704234
  • Wong EH, Levi DM, McGraw PV. Spatial interactions reveal inhibitory cortical networks in human amblyopia. Vision Res. 2005 Oct;45(21):2810-9. doi: 10.1016/j.visres.2005.06.008.

    PubMed 16040080

Questions about this trial

What is this clinical trial studying?

A study testing Visual acuity tests in people with Amblyopia, run by Anglia Ruskin University at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Oct 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Acuity (LogMAR) (time frame: Visual acuities for each participant were measured at a single time point, on a single day; day one of each participants' recruitment.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03505606, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in